For citations:

Kolyadina I.V. Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice. Tumors of female reproductive system. 2021;17(2):58‑67. (In Russ.) https://doi.org/10.17650/1994-4098-2021-17-2-58-67